Mycophenolate sodium in the treatment of corticosteroid-refractory non-infectious inflammatory uveitis (MySTRI study).

Tony S ChenWing Man TsangIjilmurun Enkh-AmgalanYih-Shiou Hwang

Published in: Eye (London, England) (2020)

MPS is an effective steroid-sparing drug for the treatment of CRU. The effect seen was not only during the 6 months of therapy, but also extended to 12 months to maintain BCVA and inflammation control. The side effects were acceptable.

Keyphrases

oxidative stress
stem cells
rheumatoid arthritis
bone marrow
systemic lupus erythematosus
ankylosing spondylitis
replacement therapy
cell therapy